knowledge -WSS

knowledge

author：leisure time 2025-10-02 22:39:47 - browse：846

Boxes of Wegovy — pharma coverage from STAT — Carsten Snejbjerg/Bloomberg

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.

Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Physician groups backed by private equity giant lobby on mergers

hotspot

WSS

With psoriasis trial ahead, Alumis raises $259 million

How to bring more disabled researchers into academia

IVF, abortion rights issues kick off Biden’s State of the Union

NIH launches clinical trials and new research office for long Covid

Amazon expands telehealth clinic nationwide

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

explore

knowledge

hotspot

Psychedelics group wrestles with new pharma identity

Sage hopes for a blockbuster in antidepressant now before FDA

State Dept. review finds Biden bears some blame for Afghanistan failures

NIH launches clinical trials and new research office for long Covid

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Bright Health sells Medicare Advantage business to Molina

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Novavax promises a turnaround & Lilly roils the obesity market

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

explore

EQRx, failed developer of low

A deep dive into Applied Therapeutics’ data, and questions on Cassava

No plane should take off without an EpiPen onboard

Physician groups backed by private equity giant lobby on mergers

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

No plane should take off without an EpiPen onboard

knowledge

hotspot

hotspot

leisure time